Search

Displaying results 3711 - 3720 of 5040 in total
  1. Drug

    Rogocekib

    go.drugbank.com/drugs/DB21739
    Investigational

    Rogocekib has a monoisotopic molecular weight of 408.15 Da.

  2. Drug

    Moxidectin

    go.drugbank.com/drugs/DB11431
    ApprovedInvestigationalVet approved

    Due to these modifications, moxidectin is classified as a second generation macrocyclic lactone.

  3. Drug

    Dosulepin

    go.drugbank.com/drugs/DB09167
    ApprovedInvestigational

    It is not FDA-approved due to low therpeutic index and significant toxicity in overdose.

  4. Drug

    Grapiprant

    go.drugbank.com/drugs/DB12836
    InvestigationalVet approved

    Grapiprant, also known as AT-001 and CJ-023, is a drug from the piprant class. These molecules were derived from acylsulfonamide and are characterized to be a novel series of para-N-acylaminomethylbenzoic acid known to be prostaglandin r...

  5. Drug

    Ibopamine

    go.drugbank.com/drugs/DB13316
    Experimental

    Categories: Dopamine D1 Receptor Agonists
  6. Drug

    Cilansetron

    go.drugbank.com/drugs/DB04885
    Experimental

    Cilansetron is a 5HT-3 antagonist made by Solvay Pharmaceuticals that is currently under trial phase in the EU and US.

  7. Drug

    Lazuvapagon

    go.drugbank.com/drugs/DB19046
    Investigational

    Lazuvapagon is under investigation in clinical trial NCT03116191 (Trial of SK-1404 for Nocturia Due to Nocturnal Polyuria in Japanese Subjects).

  8. Drug

    10-hydroxycamptothecin

    go.drugbank.com/drugs/DB12385
    Experimental

    10-hydroxycamptothecin is under investigation in clinical trial NCT00956787 (Study of AR-67 (DB-67) in Myelodysplastic Syndrome (MDS)).

  9. Drug

    Iomethin I-131

    go.drugbank.com/drugs/DB21079
    Experimental

    Iomethin I-131 has a monoisotopic molecular weight of 359.06 Da.

  10. Drug

    AP5280

    go.drugbank.com/drugs/DB05112
    Experimental

    AP5280 is a novel N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-bound platinum (Pt) therapeutic designed to increase the therapeutic index relative to conventional, small-molecule platinum agents.